Axsome Therapeutics (AXSM) Set to Release Earnings on Monday

Axsome Therapeutics (NASDAQ:AXSM) is projected to post its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect Axsome Therapeutics to announce earnings of ($0.6342) per share and revenue of $249.19 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 2, 2026 at 8:00 AM ET.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, August 10th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.10). The firm had revenue of $218.38 million during the quarter, compared to the consensus estimate of $221.11 million. Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. On average, analysts expect Axsome Therapeutics to post ($3.04) EPS for the current fiscal year and $3.51 EPS for the next fiscal year.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $144.43 on Friday. The stock has a market cap of $7.57 billion, a P/E ratio of -38.51 and a beta of 0.86. The company has a current ratio of 1.43, a quick ratio of 1.34 and a debt-to-equity ratio of 1.52. The stock’s 50-day moving average is $184.76 and its 200-day moving average is $198.93. Axsome Therapeutics has a 1-year low of $123.50 and a 1-year high of $260.19.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on AXSM. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Axsome Therapeutics from $280.00 to $267.00 and set a “buy” rating for the company in a research note on Tuesday, September 29th. UBS Group reissued a “buy” rating on shares of Axsome Therapeutics in a research note on Monday, August 24th. BMO Capital Markets started coverage on Axsome Therapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $310.00 price objective for the company. Zacks Research upgraded Axsome Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 18th. Finally, Morgan Stanley lowered their target price on Axsome Therapeutics from $251.00 to $247.00 and set an “equal weight” rating for the company in a research report on Friday, September 25th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $274.68.

Insider Activity

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 4,660 shares of Axsome Therapeutics stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $213.95, for a total value of $997,007.00. Following the completion of the sale, the chief executive officer directly owned 7,229 shares in the company, valued at approximately $1,546,644.55. The trade was a 39.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Mark L. Jacobson sold 10,000 shares of Axsome Therapeutics stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total value of $2,086,500.00. Following the completion of the sale, the chief operating officer owned 10,000 shares of the company’s stock, valued at approximately $2,086,500. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 59,664 shares of company stock worth $12,624,805. 20.60% of the stock is owned by corporate insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in New York, the company develops medicines for conditions with significant unmet medical needs, including depression, narcolepsy, excessive daytime sleepiness, and other neurological disorders.

Axsome’s commercial products include Auvelity (dextromethorphan and bupropion), an oral treatment approved in the United States for major depressive disorder in adults, and Sunosi (solriamfetol), a therapy for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.